Posted by Leanne Kodsmann on
Christopher R. Phaneuf, Kyle J. Seamon, Tyler P. Eckles, Anchal Sinha, Joseph S. Schoeniger, Brooke Harmon, Robert J. Meagher, Vinay V. Abhyankar and Chung-Yan Koh
Issue 5, 2019
"... The potential for accidental exposure, malicious use, or undesirable persistence of Cas9 therapeutics and off-target genome effects highlight the need for detection assays. Here we report a centrifugal microfluidic platform for the measurement of both Cas9 protein levels and nuclease activity ... Whole blood, serum, and plasma were purchased from Innovative Research (Novi, MI). These biomaterials were pooled, deidentified, publicly-available specimens from healthy human donors and therefore exempt from IRB/HSB review. All work conducted with risk group 2 biomaterials was reviewed by the IBC (2019-06-05-CK) and universal precautions were observed. ..."
Related products available from Innovative Research also include: